Comparative Pharmacology
Head-to-head clinical analysis: ALOGLIPTIN versus DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOGLIPTIN versus DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE.
ALOGLIPTIN vs DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal renal tubule, reducing plasma glucose independent of insulin secretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, increasing insulin release and decreasing glucagon secretion.
25 mg orally once daily
Oral: 1 tablet (dapagliflozin 5 mg / saxagliptin 5 mg) once daily, taken with or without food, in combination with metformin or other glucose-lowering agents.
None Documented
None Documented
Clinical Note
moderateAlogliptin + Gatifloxacin
"Alogliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateAlogliptin + Rosoxacin
"Alogliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateAlogliptin + Levofloxacin
"Alogliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateAlogliptin + Trovafloxacin
"Alogliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Dapagliflozin: Terminal half-life ~12.9 hours (supports once-daily dosing). Saxagliptin: Terminal half-life ~2.5 hours, but active metabolite 5-hydroxy saxagliptin has half-life ~3.1 hours (supports once-daily dosing due to prolonged DPP-4 inhibition).
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Dapagliflozin: ~75% renal excretion (21% unchanged, 50% as major metabolite 3-O-glucuronide), ~21% fecal. Saxagliptin: ~75% renal excretion (12% unchanged, 22% as major metabolite 5-hydroxy saxagliptin, 41% as other metabolites), ~22% fecal.
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor